Coagulation in Cirrhosis (COUCH)
Liver Cirrhosis
About this trial
This is an interventional treatment trial for Liver Cirrhosis focused on measuring Patient Blood Management, Platelet Concentrates, Transfusion, Coagulation
Eligibility Criteria
Inclusion Criteria: Patients at the University Hospital of Vienna with diagnosed liver cirrhosis and deranged coagulation parameters (INR >1,5 AND/ OR platelet count <50 G/L) who are scheduled for one of the following elective invasive interventions of the liver Biopsy or puncture Microwave ablation (MWA) or radiofrequency ablation (RFA) Transjugular intrahepatic portosystemic shunt (TIPS) Percutaneous transhepatic cholangiography drain (PTCD) Exclusion Criteria: Missing informed consent or inability to consent Age < 18 years Pregnancy or breastfeeding Manifest ascites Chronic kidney injury stage G4 or G5, KDIGO Uninterrupted anticoagulant therapy, except for acetylsalicylic acid (ASA) History of bleeding or clinical signs of a hemorrhagic diathesis in the physical examination (e.g., petechia, ecchymosis, mucosal bleeding, hemorrhagic diathesis within the family, menorrhagia, prolonged bleeding after surgery)
Sites / Locations
- General Hospital of the Medical University of ViennaRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Liberal substitution of human prothrombin complex and/or platelet concentrates
Restrictive substitution of human prothrombin complex and/or thrombocytes
If INR < 1,5: 10 I.E. human prothrombin complex/kg bodyweigt/0,5 INR AND/OR If platelets < 50 G/l: ((50 G/l - measured thrombocyte concentration G/l) x total blood volume) platelet concentrate
No substitution of blood products described in the Active Comparator group.